Aura Biosciences (AURA) to Release Earnings on Thursday

Aura Biosciences (NASDAQ:AURA) is projected to post its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Aura Biosciences to post earnings of ($0.40) per share for the quarter. Individuals can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Monday, March 30th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. On average, analysts expect Aura Biosciences to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Aura Biosciences Trading Up 2.4%

Shares of AURA opened at $8.40 on Friday. The firm has a market cap of $539.28 million, a PE ratio of -4.69 and a beta of 0.37. The company’s 50 day simple moving average is $6.66 and its 200-day simple moving average is $6.05. Aura Biosciences has a 12-month low of $4.34 and a 12-month high of $9.53.

Analyst Ratings Changes

A number of equities analysts recently weighed in on AURA shares. Wall Street Zen upgraded shares of Aura Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. HC Wainwright lifted their price objective on shares of Aura Biosciences from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aura Biosciences in a research report on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $21.50.

Insider Buying and Selling

In other Aura Biosciences news, CTO Mark Plavsic sold 15,890 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $5.05, for a total value of $80,244.50. Following the completion of the sale, the chief technology officer owned 181,397 shares of the company’s stock, valued at approximately $916,054.85. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Conor Kilroy sold 11,738 shares of the firm’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $7.02, for a total value of $82,400.76. Following the completion of the sale, the insider directly owned 217,835 shares of the company’s stock, valued at approximately $1,529,201.70. This trade represents a 5.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 116,305 shares of company stock valued at $611,230 in the last quarter. Corporate insiders own 6.30% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the business. Dynamic Technology Lab Private Ltd acquired a new stake in Aura Biosciences in the third quarter valued at $157,000. JPMorgan Chase & Co. lifted its holdings in Aura Biosciences by 12.3% in the third quarter. JPMorgan Chase & Co. now owns 24,557 shares of the company’s stock valued at $152,000 after acquiring an additional 2,693 shares during the period. EntryPoint Capital LLC acquired a new stake in Aura Biosciences in the fourth quarter valued at $143,000. MetLife Investment Management LLC lifted its holdings in Aura Biosciences by 29.3% in the fourth quarter. MetLife Investment Management LLC now owns 25,031 shares of the company’s stock valued at $136,000 after acquiring an additional 5,674 shares during the period. Finally, Opal Capital LLC acquired a new position in shares of Aura Biosciences during the 4th quarter worth $127,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences is a clinical?stage biopharmaceutical company focused on the development of novel virus?like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company’s platform is designed to address solid tumors in both ophthalmic and non?ophthalmic settings, leveraging precision activation via near?infrared light to induce localized tumor cell apoptosis and stimulate anti?tumor immune responses.

The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.